RT Journal Article
SR Electronic
T1 Antibody Correlates of Protection for COVID-19 Convalescent Plasma Associated with Reduced Outpatient Hospitalizations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.13.23288353
DO 10.1101/2023.04.13.23288353
A1 Park, Han-Sol
A1 Barranta, Caelan
A1 Yin, Anna
A1 Lee, John S.
A1 Caputo, Christopher A.
A1 Li, Maggie
A1 Yoon, Steve
A1 Sitaras, Ioannis
A1 Jedlicka, Anne
A1 Eby, Yolanda
A1 Ram, Malathi
A1 Fernandez, Reinaldo E.
A1 Baker, Owen R.
A1 Shenoy, Aarthi G.
A1 Mosnaim, Giselle S.
A1 Fukuta, Yuriko
A1 Patel, Bela
A1 Heath, Sonya L.
A1 Levine, Adam C.
A1 Meisenberg, Barry R.
A1 Spivak, Emily S.
A1 Anjan, Shweta
A1 Huaman, Moises A.
A1 Blair, Janis E.
A1 Currier, Judith S.
A1 Paxton, James H.
A1 Gerber, Jonathan M.
A1 Petrini, Joann R.
A1 Broderick, Patrick B.
A1 Rausch, William
A1 Cordisco, Marie Elena
A1 Hammel, Jean
A1 Greenblatt, Benjamin
A1 Cluzet, Valerie C.
A1 Cruser, Daniel
A1 Oei, Kevin
A1 Abinante, Matthew
A1 Hammitt, Laura L.
A1 Sutcliffe, Catherine G.
A1 Forthal, Donald N.
A1 Zand, Martin S.
A1 Cachay, Edward R.
A1 Raval, Jay S.
A1 Kassaye, Seble G.
A1 Marshall, Christi E.
A1 Yarava, Anusha
A1 Lane, Karen
A1 McBee, Nichol A.
A1 Gawad, Amy L.
A1 Karlen, Nicky
A1 Singh, Atika
A1 Ford, Daniel E.
A1 Jabs, Douglas A.
A1 Appel, Lawrence J.
A1 Shade, David M.
A1 Lau, Bryan
A1 Ehrhardt, Stephan
A1 Baksh, Sheriza N.
A1 Shapiro, Janna R.
A1 Ou, Jiangda
A1 Gniadek, Thomas J.
A1 Caturegli, Patrizio
A1 Wu, Jinke
A1 Ndahiro, Nelson
A1 Betenbaugh, Michael J.
A1 Ziman, Alyssa
A1 Hanley, Daniel F.
A1 Arturo, Casadevall
A1 Shoham, Shmuel
A1 Bloch, Evan M.
A1 Gebo, Kelly A.
A1 Tobian, Aaron A.R.
A1 Laeyendecker, Oliver
A1 Pekosz, Andrew
A1 Klein, Sabra L.
A1 Sullivan, David J.
YR 2023
UL http://medrxiv.org/content/early/2023/04/19/2023.04.13.23288353.abstract
AB SARS-CoV-2 antibody levels associated with reduced hospitalization risk remain undefined. Our outpatient COVID-19 convalescent plasma (CCP), placebo-controlled trial observed SARS-CoV-2 antibody levels decreasing 22-fold from matched donor units into post-transfusion seronegative recipients. Unvaccinated recipients were jointly stratified by a) early or late transfusion (≤ 5 or >5 days from symptom onset) and b) high or low post-transfusion SARS-CoV-2 antibody levels (< or ≥ geometric mean). Early treatment with high post-transfusion antibody levels reduced hospitalization risk-0/102 (0%) compared to all other CCP recipients-17/370 (4.6%; Fisher exact p=0.03) and to all control plasma recipients-35/461 (7.6%; Fisher exact p=0.001). A similar donor upper/lower antibody level and early late transfusion stratified analyses indicated significant hospital risk reduction. Pre-transfusion nasal viral loads were similar in CCP and control recipients regardless of hospitalization outcome. Therapeutic CCP should comprise the upper 30% of donor antibody levels to provide effective outpatient use for immunocompromised and immunocompetent outpatients.Competing Interest StatementTG- Paid consultant and employee of Fenwal, a Fresenius Kabi company; AC- Scientific Advisory Board of Sabtherapeutics (cow-derived human immunoglobulins COVID-19 treatment and other infectious diseases) and Ortho Diagnostics Speakers Bureau; EB- member of the FDA Blood Products Advisory Committee, Abbot Laboratories, Grifols Diagnostic Solutions and Terumo BCT: personal fee for invited educational presentations; California Institute for Regenerative Medicine: Advisor. SS reports research grants; F2G, Cidara, Ansun, Zeteo, Emergent Biosolutions: personal fees as consultant, advisory board, data safety monitoring board member; Celltrion, Adagio, Immunome, Adamis, Karyopharm, Intermountain Health: Stock options: Immunome; CS: Centers for Disease Control and Prevention, Merck, Pfizer: Research Grants. All other authors report no relevant disclosures.Clinical TrialNCT04373460Funding StatementSupported by a contract (W911QY2090012, to Dr. Sullivan) with the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense of the Department of Defense, in collaboration with the Defense Health Agency; Bloomberg Philanthropies; the State of Maryland; a grant (3R01AI152078-01S1, to Dr. Casadevall) from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID); a grant (U24TR001609-S3, to Dr. Hanley) from the NIH National Center for Advancing Translational Sciences; a grant (1K23HL151826NIH, to Dr. Bloch) from the National Heart, Lung, and Blood Institute; the Division of Intramural Research, NIAID, NIH; the Mental Wellness Foundation; the Moriah Fund; Octapharma; the Healthnetwork Foundation; and the Shear Family Foundation. The study sponsors did not contribute to the study design, the collection, analysis, and interpretation of data, and the decision to submit the paper for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board of Johns Hopkins University served as the single institutional review board. For the Center for American Indian Health sites, the protocol was independently reviewed and approved by the Navajo Nation Human Research Review Board and the Indian Health Service National Institutional Review Board. The protocol was also approved by the Human Research Protection Office of the Department of Defense. An independent medical monitor who was unaware of the trial group assignments reviewed all serious adverse events, and an independent panel of three physicians who were unaware of the trial-group assignments adjudicated Covid 19 related hospitalizations and severity. An independent data and safety monitoring board provided interim safety and efficacy reviews. The trial was conducted in accordance with the principles of the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Council for Harmonisation, and all applicable regulatory requirements. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsCCPCOVID-19 convalescent plasmaRCTrandomized controlled trial